Caribou Biosciences, Inc. (CRBU): Price and Financial Metrics
CRBU Price/Volume Stats
| Current price | $3.91 | 52-week high | $8.59 |
| Prev. close | $3.91 | 52-week low | $3.44 |
| Day low | $3.88 | Volume | 1,415,600 |
| Day high | $4.01 | Avg. volume | 1,644,391 |
| 50-day MA | $5.91 | Dividend yield | N/A |
| 200-day MA | $5.68 | Market Cap | 353.13M |
CRBU Stock Price Chart Interactive Chart >
Caribou Biosciences, Inc. (CRBU) Company Bio
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Latest CRBU News From Around the Web
Below are the latest news stories about CARIBOU BIOSCIENCES INC that investors may wish to consider to help them evaluate CRBU as an investment opportunity.
3 Gene-Editing Stocks With the Potential to Mint MillionairesGene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. |
5 Things to Know Before The Stock Market OpensThe Federal Reserve will conclude its last policy meeting of the year with a decision to hold interest rates steady expected, and Tesla issued a recall over its Autopilot drive-assistance system. Here’s what investors need to know today. |
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024-- Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT -- -- ANTLER Phase 1 trial continues dose expansion enrollment; initial dose expansion data and RP2D expected Q2 2024 -- -- Caribou plans to initiate Phase 3 pivotal trial by YE 2024 -- BERKELEY, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharma |
Caribou Biosciences, Inc. (CRBU) Upgraded to Buy: What Does It Mean for the Stock?Caribou Biosciences, Inc. (CRBU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Next-Gen Biotech: 3 Companies Leading the Charge in Gene TherapyThese three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases. |
CRBU Price Returns
| 1-mo | -28.65% |
| 3-mo | -23.63% |
| 6-mo | 0.00% |
| 1-year | -9.49% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -31.76% |
| 2023 | -8.76% |
| 2022 | -58.38% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...